Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: The ANRS CO8 APROCO-COPILOTE study

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 393-399

  Nazih, Hassan ^a   Raffi, François ^b   Taïeb, Audrey ^a   Reynes, Jacques ^c   Choutet, Patrick ^d   Cassuto, Jill Patrick ^e   Ferry, Tristan ^f   Chêne, Geneviève ^a   Leport, Catherine ^g   Bard, Jean Marie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADULT; ALLELE; ARTICLE; CELL DIFFERENTIATION; COHORT ANALYSIS; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PATIENT CODING; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; FEMALE; HIV SEROPOSITIVITY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; METABOLIC SYNDROME X; PILOT PROJECTS; POLYMORPHISM, GENETIC; PPAR ALPHA; PPAR GAMMA; PROSPECTIVE STUDIES;

EID: 84859197432     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0311     Document Type: Article

References (49)

1. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099.
2. Gervasoni C, Ridolfo AL, Trifiro G, et al.: Redistribution of body fat in HIV-infected women undergoing combined an-tiretroviral therapy. AIDS 1999;13:465-471.
3. SaintMarc T, Partisani M, Poizot Martin I, et al.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14: 37-49.
4. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12: F51-F58.
5. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23: 35-43.
6. Saves M, Raffi F, Capeau J, et al. and the Antiproteases Cohort (APROCO) Study Group: Factors related to lipody-strophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-1405.
7. Pasternak R: Adult Treatment Panel II versus Adult Treatment Panel III: What has changed and why? Am J Cardiol 2002;89(Suppl):3C-7C.
8. Grundy SM: Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrin Metab 2007;92:399-404.
9. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 2005;112:2735-2752.
10. Bard JM, Lassalle R, Capeau J, et al. and the APROCO-CO-PILOTE Study Group: Association of apolipoproteins C3 and E with the metabolic changes in HIV-infected adults treated with a protease inhibitor-containing antiretroviral therapy. Antiviral Ther 2006;11:361-370.
11. Tai ES, Demissie S, Cupples LA, et al.: Association between the PPARA L162V polymorphism and plasma lipid level: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002;22:805-810.
12. Vigouroux C, Fajas L, Khallouf E, et al.: Human peroxisome proliferator-activated receptor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998;47:490-492.
13. Deeb SS, Fajas L, Nemoto M et al.: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
14. Savage DB, Tan GD, Acerini CL, et al.: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003;52:910-917.
15. Fajas L, Auboeuf D, Raspe E, et al.: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
16. Fajas L, Fruchart JC, and Auwerx J: PPARgamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998;438:55-60.
17. Gurnell M, Savage DB, Chatterjee VK, et al.: The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003;88:2412-2421.
18. Hara K, Okada T, Tobe K, et al.: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-216.
19. Clement K, Hercberg S, Passinge B, et al.: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24: 391-393.
20. Mancini FP, Vaccaro O, Sabatino L, et al.: Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999;481466-1468.
21. Ringel J, Engeli S, Distler A, et al.: Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.
22. Koch M, Rett K, Maerker E, et al.: The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999;42:758-762.
23. Altshuler D, Hirschhorn J N, Klannemark M, et al.: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
24. Lindi VI, Uusitupa MI, Lindstrom J, et al.: Finnish Diabetes Prevention Study. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002;51:2581-2586.
25. Evans D, de Heer J, Hagemann C, et al.: Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor gamma (PPAR gamma) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109: 151-154.
26. Ridker PM, Cook NR, Cheng S, et al.: Alanine for proline substitution in the peroxisome proliferator activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003;23: 859-863.
27. Ostgren CJ, Lindblad U, Melander O, et al.: Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg hypertension and diabetes project. J Hypertens 2003;21:1657-1662.
28. Doney A, Fischer B, Frew D, et al.: Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002;3:21.
29. Al-Shali KZ, House AA, Hanley AJG, et al.: Genetic variation in PPARG encoding peroxisome proliferator-activated receptor c associated with carotid atherosclerosis. Stroke 2004; 35:2036-2040.
30. Doney ASF, Fischer B, Leese G, et al.: Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus. A Go-DARTS Study. Arterioscler Thromb Vasc Biol 2004;24:2403-2407.
31. Tai ES, Corella D, Deurenberg-Yap M, et al.: Differential effects of the C1431T and Pro12Ala PPARc gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004;45:674-685.
32. Alberti KG, Zimmet P, and Saw J: IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
33. The IDF consensus worldwide definition of the metabolic syndrome [http://www.idf.org]. Accessed October 2, 2007.
34. Dube MP, Sprecher D, Henry WK, et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendation of the adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-1224.
35. Miller SA, Dykes DD, and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1989;16:1215.
36. Li S, Chen W, Srinivasan SR et al.: The peroxisome proliferator-activated receptor-c2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood. The Bogalusa Heart Study. Diabetes 2003;52:1265-1269.
37. Frederiksen L, Brodbaek K, Fenger M, et al.: Studies of the Pro12Ala polymorphism of the PPAR-c gene in the Danish MONICA cohort: Homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002;87:3989-3992.
38. Meirhaeghe A, Cottel D, Amouyel P, et al.: Association between peroxisome proliferator-activated receptor c haplotypes and the metabolic syndrome in French men and women. Diabetes 2005;54:3043-3048.
39. Uthurralt J, Gordish-Dressman H, Bradbury M, et al.: PPARa L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. Br Med Gen J 2007; 8:55 E-Pub.
40. Tai ES, Corella D, Demissie S, et al.: Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 2005;135:397-403.
41. Mori H, Ikegami H, Kawaguchi Y, et al.: The Pro12-Ala substitution in PPAR-c is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-894.
42. Douglas JA, Erdos MR, Watanabe RM, et al.: The peroxisome proliferator-activated receptor-c2 Pro12Ala variant: Association with type 2 diabetes and trait differences. Diabetes 2001;50:886-890.
43. Meirhaeghe A, Fajas L, Helbecque N, et al.: A genetic polymorphism of the peroxisome proliferators-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-440.
44. Globerman H, Zauberman Y, Makarov T, et al.: Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene in HAIRAN syndrome with obesity. Clin Endocrinol 2000;52:479-485.
45. Zanone Poma B, Riva A, Nasi M, et al. for the Icona Foundation Study Group: Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008;22:1769-1778.
46. Amedo M, Taffé P, Sahli R, et al.: Contribution of 20 single polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genom 2007;17: 755-764.
47. Rudkowska I, Garenc C, et al.: Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. Genes Nutr 2009;4:199-205.
48. Rudkowska I, Verreault M, Barbier O, et al.: Differences in transcriptional activation by the two allelic (L162V polymorphic) variants of PPARalpha after omega-3 fatty acids treatment. PPAR Res 2009;369602.
49. Masugi J, Tamori Y, Mori H, et al.: Inhibitory effect of proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-g2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268:178-182.